Rezolute reports positive topline results from phase 2 proof of concept study of rz402 in patients with diabetic macular edema (dme)

Met primary study endpoints: good safety profile and reduction in central subfield thickness (cst) first oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention virtual investor event to be held today at 5:30pm et redwood city, calif., may 21, 2024 (globe newswire) -- rezolute, inc. (nasdaq: rzlt) (“rezolute” or the “company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced positive topline results from the phase 2 clinical study of rz402 in patients with dme who are naÏve to or have received limited anti-vascular growth factor (anti-vegf) injections.
RZLT Ratings Summary
RZLT Quant Ranking